Aldag Edward K JR

SEC source: 0001193125-26-417145 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,576,342

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001193125-26-298832 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,685,775

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001193125-26-148528 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,795,208

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001193125-26-009135 · ownership.xml · nonDerivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,904,641

F4 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001193125-26-009135 · ownership.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,093,592

F3 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2026.

SEC source: 0001193125-26-009135 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,993,885

F1 · shares: Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's reduction of overall debt and cash revenue growth, as defined and set by our compensation committee, over the period from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award for 2026 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds and further adjusted pursuant to modifier provisions in the award that are based on the Company's total return to shareholders.

F2 · balance_after: The total amount of securities beneficially owned following the reported transaction includes a reduction of shares that were forfeited due to only partially satisfying the performance thresholds established as part of the 2023 Performance Share Award.

SEC source: 0001193125-25-290062 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,079,412

F1 · shares: Represents a gift of shares of common stock to a charitable organization for a planned contribution that was pledged several years ago.

SEC source: 0001193125-25-233765 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,274,012

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-25-094663 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,354,656

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-25-055630 · ownership.xml · derivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,214,041

Underlying: Common stock, par value $0.001 · 414,041 shares

Expires not disclosed

F4 · shares: The restricted stock units were granted under the Medical Properties Trust, Inc. ("the Company") Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified Company total shareholder return ("TSR") hurdles during the three-year period beginning April 15, 2025 (the "Grant Date") as follows: (i) if the Company's TSR reaches 20%, 100% of the restricted stock units will be earned; (ii) if the Company's TSR reaches 40%, 200% of the restricted stock units will be earned; and (iii) if the Company's TSR reaches 60%, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average, determined quarterly; provided, however, following the end of such three-year performance period, achievement of performance between specific TSR hurdles described above will be determined using straight line linear interpolation (continued on footnote 5).

F5 · shares: Earned restricted stock units will be settled in cash (based on the average price of the Company's common stock over the five trading days ending on the applicable vesting date) in equal quarterly installments over one year following the date the restricted stock units are earned, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding performance metrics following the end of the three-year performance period, subject to the grantee's continued employment through such date.

F4 · derivative.exercise_date: The restricted stock units were granted under the Medical Properties Trust, Inc. ("the Company") Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified Company total shareholder return ("TSR") hurdles during the three-year period beginning April 15, 2025 (the "Grant Date") as follows: (i) if the Company's TSR reaches 20%, 100% of the restricted stock units will be earned; (ii) if the Company's TSR reaches 40%, 200% of the restricted stock units will be earned; and (iii) if the Company's TSR reaches 60%, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average, determined quarterly; provided, however, following the end of such three-year performance period, achievement of performance between specific TSR hurdles described above will be determined using straight line linear interpolation (continued on footnote 5).

F5 · derivative.exercise_date: Earned restricted stock units will be settled in cash (based on the average price of the Company's common stock over the five trading days ending on the applicable vesting date) in equal quarterly installments over one year following the date the restricted stock units are earned, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding performance metrics following the end of the three-year performance period, subject to the grantee's continued employment through such date.

F4 · derivative.expiration_date: The restricted stock units were granted under the Medical Properties Trust, Inc. ("the Company") Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified Company total shareholder return ("TSR") hurdles during the three-year period beginning April 15, 2025 (the "Grant Date") as follows: (i) if the Company's TSR reaches 20%, 100% of the restricted stock units will be earned; (ii) if the Company's TSR reaches 40%, 200% of the restricted stock units will be earned; and (iii) if the Company's TSR reaches 60%, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average, determined quarterly; provided, however, following the end of such three-year performance period, achievement of performance between specific TSR hurdles described above will be determined using straight line linear interpolation (continued on footnote 5).

F5 · derivative.expiration_date: Earned restricted stock units will be settled in cash (based on the average price of the Company's common stock over the five trading days ending on the applicable vesting date) in equal quarterly installments over one year following the date the restricted stock units are earned, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding performance metrics following the end of the three-year performance period, subject to the grantee's continued employment through such date.

SEC source: 0000950170-25-055630 · ownership.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,471,817

F3 · shares: Shares vest at the beginning of each calendar quarter ending March 31, 2028.

SEC source: 0000950170-25-055630 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,483,766

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

F2 · balance_after: The total amount of securities beneficially owned following the reported transaction includes a decrease of 234,566 shares as a result of forfeitures related to previously disclosed share awards.

SEC source: 0000950170-25-050801 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,738,675

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-25-002470 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,768,871

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-24-112453 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,805,041

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-24-082205 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,856,133

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-24-047148 · ownership.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,907,225

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-24-047148 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,958,317

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-24-039718 · ownership.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,197,350

F2 · shares: Represents additional shares earned and vested immediately under the 2023 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, decreased pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders.

SEC source: 0000950170-24-039718 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,093,576

F1 · shares: Represents net additional shares earned and vested immediately under the 2021 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, decreased pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders.

SEC source: 0000950170-24-030343 · ownership.xml · derivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,800,000

Underlying: Common stock, par value $0.001 · 1,800,000 shares

Expires not disclosed

F2 · shares: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period following March 8, 2024 (the "Grant Date") as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 3).

F3 · shares: Earned restricted stock units will be settled in cash in equal quarterly installments over two years following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

F2 · derivative.exercise_date: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period following March 8, 2024 (the "Grant Date") as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 3).

F3 · derivative.exercise_date: Earned restricted stock units will be settled in cash in equal quarterly installments over two years following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

F2 · derivative.expiration_date: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period following March 8, 2024 (the "Grant Date") as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 3).

F3 · derivative.expiration_date: Earned restricted stock units will be settled in cash in equal quarterly installments over two years following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

SEC source: 0000950170-24-030343 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,080,457

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2024.

SEC source: 0000950170-24-031824 · ownership.xml · derivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,800,000

Underlying: Common stock, par value $0.001 · 1,800,000 shares

Expires not disclosed

F1 · shares: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period ending on December 31, 2027 (previously reported as March 8, 2028) as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 2).

F2 · shares: Earned restricted stock units will be settled in cash in equal quarterly installments over one year (previously reported as two years) following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

F1 · derivative.exercise_date: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period ending on December 31, 2027 (previously reported as March 8, 2028) as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 2).

F2 · derivative.exercise_date: Earned restricted stock units will be settled in cash in equal quarterly installments over one year (previously reported as two years) following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

F1 · derivative.expiration_date: The restricted stock units were granted under the Medical Properties Trust, Inc. Amended and Restated 2019 Equity Incentive Plan and will be earned based on the achievement of specified increases in the price of the Company's common stock during the four-year period ending on December 31, 2027 (previously reported as March 8, 2028) as follows: (i) if the Company's share price increases to $7.00, 100% of the restricted stock units will be earned; (ii) if the Company's share price increases to $8.50, 200% of the restricted stock units will be earned; and (iii) if the Company's share price increases to $10.00, 300% of the restricted stock units will be earned. The actual number of restricted stock units to be earned will be determined based on the trailing 20-trading day average closing price of the Company's common stock (continued on footnote 2).

F2 · derivative.expiration_date: Earned restricted stock units will be settled in cash in equal quarterly installments over one year (previously reported as two years) following the date the restricted stock units are earned, subject to the grantee's continued employment through such date, provided that all unsettled earned restricted stock units will be settled in cash in full on the date that the Compensation Committee makes the final determination regarding achievement of the performance metrics following the end of the four year performance period. Each restricted stock unit will be settled in cash based on the value of a share of common stock.

SEC source: 0000950170-24-003090 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,207,251

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0000950170-23-053139 · ownership.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,226,400

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001287865-23-000039 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,252,712

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001287865-23-000005 · primary_doc.xml · nonDerivative · entry 5

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,322,694

F5 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001287865-23-000005 · primary_doc.xml · nonDerivative · entry 4

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,552,697

F4 · shares: Represents additional shares earned under the 2022 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, adjusted pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders. The shares vested in January 2023.

SEC source: 0001287865-23-000005 · primary_doc.xml · nonDerivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,491,732

F3 · shares: Represents additional shares earned under the 2020 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, adjusted pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders. The shares vested in January 2023.

SEC source: 0001287865-23-000024 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,534,408

F1 · shares: Reflects a decrease of 18,289 shares previously reported as earned under the 2022 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, adjusted pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders.

SEC source: 0001287865-23-000005 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,376,450

F2 · shares: Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's EBITDA and strategic transactions, as defined and set by our compensation committee, over the period from January 1, 2023 through December 31, 2025, with the opportunity to earn up to one third of the award for 2023 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds and further adjusted pursuant to modifier provisions in the award that are based on the Company's total return to shareholders.

SEC source: 0001287865-23-000005 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,753,808

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2023.

SEC source: 0001287865-23-000004 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,433,053

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligation. This does not constitute a sale transaction.

SEC source: 0001287865-22-000025 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,451,334

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001287865-22-000022 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,474,270

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligation. This does not constitute a sale transaction.

SEC source: 0001287865-23-000017 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,428,398

F1 · shares: Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

SEC source: 0001287865-22-000018 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,497,206

F1 · price: This transaction was executed in multiple trades at prices ranging from $21.19 to $21.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001287865-22-000005 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,112,206

F2 · shares: Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's per share funds from operations, EBITDA, and acquisitions, as defined and set by our compensation committee, over the period from January 1, 2022 through December 31, 2024, with the opportunity to earn up to one third of the award for 2022 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds and further adjusted pursuant to modifier provisions in the award that are based on the Company's total return to shareholders.

SEC source: 0001287865-22-000005 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,746,417

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2022.

SEC source: 0001287865-22-000001 · primary_doc.xml · nonDerivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,557,980

F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the common shares vesting (pursuant to our 2019 Equity Incentive Plan) and does not represent a sale by the Reporting Person.

SEC source: 0001287865-22-000001 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,184,756

F2 · shares: Represents additional shares earned under the 2021 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement, adjusted pursuant to the modifier provisions in the award that were based on the Company's total return to shareholders. The shares vested in January 2022.

SEC source: 0001287865-22-000001 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,029,976

F1 · shares: Represents shares earned under the 2019 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on how the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. The shares vested in January 2022.

SEC source: 0001287865-21-000017 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,251,167

F1 · price: This transaction was executed in multiple trades at prices ranging from $21.03 to $21.32. The price reported above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001287865-21-000002 · primary_doc.xml · derivative · entry 6

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock, par value $0.001 · 111,814 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

F6 · derivative.exercise_date: The shares vested on January 1, 2021.

F6 · derivative.expiration_date: The shares vested on January 1, 2021.

SEC source: 0001287865-21-000002 · primary_doc.xml · nonDerivative · entry 5

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,052,897

F5 · shares: Represents additional shares earned under the 2018 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on how the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. The shares vested on January 1, 2021.

SEC source: 0001287865-21-000002 · primary_doc.xml · nonDerivative · entry 4

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,865,842

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · shares: Represents shares earned under the 2018 performance award equal to approximately one third of the target number of shares granted.

SEC source: 0001287865-21-000002 · primary_doc.xml · nonDerivative · entry 3

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,754,028

F3 · shares: Represents additional shares earned under the 2020 performance award based on the Company's actual performance as compared to the performance hurdles defined in the award agreement along with shares earned pursuant to the modifier provisions in the award, which allowed for more shares to be earned based on the Company's total return to shareholders and how the Company's relative total return to shareholders compared to the SNL Healthcare REIT Index. The shares vested on January 1, 2021.

SEC source: 0001287865-21-000002 · primary_doc.xml · nonDerivative · entry 2

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,581,096

F2 · shares: Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's per share funds from operations, EBITDA, and acquisitions, as defined and set by our compensation committee, over the period from January 1, 2021 through December 31, 2023, with the opportunity to earn up to one third of the award for 2021 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of specific performance thresholds.

SEC source: 0001287865-21-000002 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,187,526

F1 · shares: Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2021.

SEC source: 0001287865-21-000012 · primary_doc.xml · nonDerivative · entry 1

Aldag Edward K JR · CIK 0001331608 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,961,167